Adlai Nortye Secures $150 Million in Private Equity Placement

(SeaPRwire) –   SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 — Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotech firm dedicated to creating novel cancer treatments, today announced it has secured a securities purchase agreement for a private investment in public equity (PIPE) financing. The deal is anticipated to generate gross proceeds of roughly $150.0 million, prior to the deduction of fees for placement agents and other offering expenses.

This oversubscribed financing attracted a mix of new and current institutional investors. New participants feature Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management, Kalehua Capital, and DAFNA Capital Management, among others. They are joined by existing investors such as Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital, Squadron Capital Management, and Superstring Capital Management.

Under the terms of the private placement, the Company will sell 11,320,755 American Depositary Shares (ADSs) at $13.25 per ADS. This price matches the closing price of the Company’s ADSs on the Nasdaq Global Market as of April 15, 2026. The offering is scheduled to conclude on April 17, 2026, pending the fulfillment of standard closing conditions.

“We are thrilled to unite this consortium of top-tier healthcare investors behind Adlai Nortye and our innovative, potentially best-in-class therapies targeting RAS,” stated Carsten Lu, Chairman and CEO of Adlai Nortye. “We appreciate our investors’ trust in the extensive promise of our RAS-targeting pipeline and our next-generation ADC payload platform, RASiCA™, alongside their dedication to our goal of turning lethal cancers into manageable, and ultimately curable, conditions.”

Leerink Partners, Cantor, Lucid Capital Markets, H.C. Wainwright & Co., and Jones are serving as the joint placement agents for this transaction.

The securities offered in this private placement have not been registered under the Securities Act of 1933, as amended, or relevant state securities laws. Consequently, they may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration rules. Adlai Nortye has committed to filing a registration statement with the SEC to register the resale of the ADSs issued in this offering.

This announcement is not an offer to sell or a solicitation of an offer to buy these securities, nor shall any sale occur in any jurisdiction where such an offer, solicitation, or sale would be illegal before registration or qualification under the securities laws of that jurisdiction.

About Adlai Nortye

Adlai Nortye (Nasdaq: ANL) is a worldwide clinical-stage biopharmaceutical company leading the quest to discover and develop new cancer therapies. Utilizing its dual research and development footprint in the United States and China, the company is assembling a strong portfolio of drug candidates concentrated on two primary domains: (1) RAS-targeting therapies: The company is addressing RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) that delivers a powerful pan-RAS(ON) inhibitor precisely to tumors. (2) Next-generation cancer immunotherapies: Candidates include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor. Both are engineered to stimulate cancer immunity through innovative mechanisms.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements can often be identified by words like “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “target,” “will,” “would,” or similar expressions, or their negatives. All statements that are not historical facts are forward-looking statements, including, without limitation, statements regarding the anticipated closing of the private placement, the company’s cash runway, and plans for using the proceeds. These statements involve risks and uncertainties detailed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F, earnings releases on Form 6-K, and other SEC filings. Any forward-looking statements speak only as of the date of this release. The Company disclaims any obligation to update these statements publicly, whether due to new information, future events, or otherwise, except as mandated by law.

Company contact:
Investor Relations
Email: ir@adlainortye.com